Sun, Zeguo
Zhang, Rui
Zhang, Xiao
Sun, Yifei
Liu, Pengpeng
Francoeur, Nancy
Han, Lei
Lam, Wan Yee
Yi, Zhengzi
Sebra, Robert
Walsh, Martin
Yu, Jinpu
Zhang, Weijia
Article History
Received: 1 February 2022
Accepted: 4 July 2022
First Online: 16 July 2022
Declarations
:
: This project was approved by the Ethics Committee of Tianjin Medical University (Approved No.: Ek2020111) and written informed consents were obtained from the patients. All experiments were performed in accordance with the principles of the Declaration of Helsinki.
: Not applicable.
: W.Z. reports personal fees from VericiDx and the following patents: (i) Patents US provisional patent application F&R ref 27527-0134P01, serial no. 61/951,651, filled March 2014: Method for identifying kidney allograft recipients at risk for chronic injury; (ii) US provisional patent application: Methods for diagnosing risk of renal allograft fibrosis and rejection (miRNA); (iii) US provisional patent application: Method for diagnosing subclinical acute rejection by RNA sequencing analysis of a predictive gene set; and (iv) US provisional patent application: Pretransplant prediction of posttransplant acute rejection. PJO’C is a consultant for CSL Behring and Vitaeris. All the other authors declared no competing interests.